arrow_back Back to App

Access to Experimental Drugs: Expanding Right to Try Law

This bill aims to make it easier for patients with serious illnesses to access experimental drugs. The changes will allow the use of Schedule I substances that have completed initial trials under the "Right to Try" program. This means patients may have a chance at treatment when other options have failed.
Key points
Expands the "Right to Try" program to include Schedule I substances if they have completed initial clinical trials.
Allows patients with serious illnesses to access potentially groundbreaking therapies that are under investigation but not yet widely available.
Aims to remove legal barriers that previously prevented access to these drugs, despite their potential.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_8440
Sponsor: Rep. Blumenauer, Earl [D-OR-3]
Process start date: 2022-07-20
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Right to Try Clarification Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_8440.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2022-07-20.

What are the main provisions?

Key points include:

  • Expands the "Right to Try" program to include Schedule I substances if they have completed initial clinical trials.
  • Allows patients with serious illnesses to access potentially groundbreaking therapies that are under investigation but not yet widely available.
  • Aims to remove legal barriers that previously prevented access to these drugs, despite their potential.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Blumenauer, Earl [D-OR-3].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Crime, Terrorism, and Homeland Security.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Health Courts and Law